Table 1.
Frequency of polymorphisms that affect antiretroviral drug response in Caucasians and individuals of African descent.
|
HLA-dependent hypersensitivity reactions
| |||
|---|---|---|---|
| Drug(s) | Polymorphism |
Prevalence
|
|
| Caucasian | African descent | ||
| Abacavir | HLA-B*5701 | 5.3%12 | 2.5%12 |
| Adverse reactions resulting from altered pharmacokenetics | |||
| EFV, NVP | CYP2B6 516G→T | 3%3 | 20%3 |
| EFV, NVP | MDR1 3435C→T | 49.7%22 | 12.6%22 |
| EFV, NVP | CYP3 A4*1B | 5.9%22 | 59.2%22 |
| EFV, NVP | CYP3 A5*3 | 91.1%22 | 28.1%22 |
| Atherogenic dyslipidemia | |||
| Protease Inhibitor | ApoC3 haplotype: −482C/−455T/Intron I G/Gly34Gly C/SstI (3238) C |
45.5%49 | 10.8%49 |
| Protease Inhibitor | ApoC3 haplotype: −482C/−455C/Intron I G/Gly34Gly C/SstI (3238) C |
12.1%49 | 1.5%49 |
| Protease Inhibitor | ApoC3 haplotype: −482C/−455T/Intron I G/Gly34Gly T/SstI (3238) C |
10.5%49 | 6.3%49 |
| Protease Inhibitor | ApoC3 haplotype: −482T/−455C/Intron I C/Gly34Gly C/SstI (3238) C |
12.4%49 | 57.1%49 |
| Protease Inhibitor | ApoC3 haplotype: −482T/−455C/Intron I C/Gly34Gly T/SstI (3238) G |
8.2%49 | 8.2%49 |